Oyster Point Pharma has been granted a patent for methods and pharmaceutical formulations to treat dry eye disease. The patent involves administering varenicline through nasal spray to activate the trigeminal nerve in individuals suffering from the condition. GlobalData’s report on Oyster Point Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Oyster Point Pharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Oyster Point Pharma, was a key innovation area identified from patents.

Treatment of dry eye disease by activating trigeminal nerve

Source: United States Patent and Trademark Office (USPTO). Credit: Oyster Point Pharma Inc

A recently granted patent (Publication Number: US11911380B2) discloses a method for activating the trigeminal nerve, anterior ethmoidal nerve, and nasolacrimal reflex in individuals by administering varenicline through local nasal cavity spray. The method involves administering a therapeutically effective amount of varenicline, ranging from 5 to 1000 micrograms, in a liquid pharmaceutical formulation containing varenicline or its salt and inactive ingredients. The concentration of varenicline in the formulation falls between 0.1 mg/mL and 10 mg/mL, ensuring targeted activation without significant psychoactive side effects or vomiting.

Furthermore, the patent outlines the selective binding of varenicline to peripheral nicotinic acetylcholine receptors, emphasizing the precise dosage range of 5 to 500 micrograms for effective activation. The pharmaceutical formulation includes a phosphate buffer or phosphate citrate buffer with a pH range of 5.0 to 7.4, ensuring stability and compatibility for nasal administration. The method aims to activate these nerves and reflexes without causing undesirable side effects, offering a novel approach to therapeutic interventions involving varenicline administration through nasal spray for targeted trigeminal nerve activation.

To know more about GlobalData’s detailed insights on Oyster Point Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies